Cargando…
Human complement component C3 N-glycome changes in type 1 diabetes complications
AIM: Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glycosylation and type 1 diabetes (T1D), particularly linking serum N-glycan changes with complicati...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244649/ https://www.ncbi.nlm.nih.gov/pubmed/37293493 http://dx.doi.org/10.3389/fendo.2023.1101154 |
_version_ | 1785054687732432896 |
---|---|
author | Šoić, Dinko Štambuk, Jerko Tijardović, Marko Keser, Toma Lauc, Gordan Bulum, Tomislav Lovrenčić, Marijana Vučić Rebrina, Sandra Vučković Tomić, Martina Novokmet, Mislav Smirčić-Duvnjak, Lea Gornik, Olga |
author_facet | Šoić, Dinko Štambuk, Jerko Tijardović, Marko Keser, Toma Lauc, Gordan Bulum, Tomislav Lovrenčić, Marijana Vučić Rebrina, Sandra Vučković Tomić, Martina Novokmet, Mislav Smirčić-Duvnjak, Lea Gornik, Olga |
author_sort | Šoić, Dinko |
collection | PubMed |
description | AIM: Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glycosylation and type 1 diabetes (T1D), particularly linking serum N-glycan changes with complications accompanying the disease. Moreover, the role of complement component C3 in diabetic nephropathy and retinopathy has been implicated, and C3 N-glycome was found to be altered in young T1D patients. Therefore, we investigated associations between C3 N-glycan profiles and albuminuria and retinopathy accompanying T1D, as well as glycosylation connection with other known T1D complication risk factors. RESEARCH DESIGN AND METHODS: Complement component C3 N-glycosylation profiles have been analyzed from 189 serum samples of T1D patients (median age 46) recruited at a Croatian hospital centre. Using our recently developed high-throughput method, relative abundances of all six of the C3 glycopeptides have been determined. Assessment of C3 N-glycome interconnection with T1D complications, hypertension, smoking status, estimated glomerular filtration rate (eGFR), glycaemic control and duration of the disease was done using linear modelling. RESULTS: Significant changes of C3 N-glycome in severe albuminuria accompanying type 1 diabetes were observed, as well as in T1D subjects with hypertension. All except one of the C3 glycopeptides proved to be associated with measured HbA1c levels. One of the glycoforms was shown to be changed in non-proliferative T1D retinopathy. Smoking and eGFR showed no effect on C3 N-glycome. Furthermore, C3 N-glycosylation profile was shown to be independent of disease duration. CONCLUSION: This study empowered the role of C3 N-glycosylation in T1D, showing value in distinguishing subjects with different diabetic complications. Being independent of the disease duration, these changes may be associated with the disease onset, making C3 N-glycome a potential novel marker of the disease progression and severity. |
format | Online Article Text |
id | pubmed-10244649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102446492023-06-08 Human complement component C3 N-glycome changes in type 1 diabetes complications Šoić, Dinko Štambuk, Jerko Tijardović, Marko Keser, Toma Lauc, Gordan Bulum, Tomislav Lovrenčić, Marijana Vučić Rebrina, Sandra Vučković Tomić, Martina Novokmet, Mislav Smirčić-Duvnjak, Lea Gornik, Olga Front Endocrinol (Lausanne) Endocrinology AIM: Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glycosylation and type 1 diabetes (T1D), particularly linking serum N-glycan changes with complications accompanying the disease. Moreover, the role of complement component C3 in diabetic nephropathy and retinopathy has been implicated, and C3 N-glycome was found to be altered in young T1D patients. Therefore, we investigated associations between C3 N-glycan profiles and albuminuria and retinopathy accompanying T1D, as well as glycosylation connection with other known T1D complication risk factors. RESEARCH DESIGN AND METHODS: Complement component C3 N-glycosylation profiles have been analyzed from 189 serum samples of T1D patients (median age 46) recruited at a Croatian hospital centre. Using our recently developed high-throughput method, relative abundances of all six of the C3 glycopeptides have been determined. Assessment of C3 N-glycome interconnection with T1D complications, hypertension, smoking status, estimated glomerular filtration rate (eGFR), glycaemic control and duration of the disease was done using linear modelling. RESULTS: Significant changes of C3 N-glycome in severe albuminuria accompanying type 1 diabetes were observed, as well as in T1D subjects with hypertension. All except one of the C3 glycopeptides proved to be associated with measured HbA1c levels. One of the glycoforms was shown to be changed in non-proliferative T1D retinopathy. Smoking and eGFR showed no effect on C3 N-glycome. Furthermore, C3 N-glycosylation profile was shown to be independent of disease duration. CONCLUSION: This study empowered the role of C3 N-glycosylation in T1D, showing value in distinguishing subjects with different diabetic complications. Being independent of the disease duration, these changes may be associated with the disease onset, making C3 N-glycome a potential novel marker of the disease progression and severity. Frontiers Media S.A. 2023-05-24 /pmc/articles/PMC10244649/ /pubmed/37293493 http://dx.doi.org/10.3389/fendo.2023.1101154 Text en Copyright © 2023 Šoić, Štambuk, Tijardović, Keser, Lauc, Bulum, Lovrenčić, Rebrina, Tomić, Novokmet, Smirčić-Duvnjak and Gornik https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Šoić, Dinko Štambuk, Jerko Tijardović, Marko Keser, Toma Lauc, Gordan Bulum, Tomislav Lovrenčić, Marijana Vučić Rebrina, Sandra Vučković Tomić, Martina Novokmet, Mislav Smirčić-Duvnjak, Lea Gornik, Olga Human complement component C3 N-glycome changes in type 1 diabetes complications |
title | Human complement component C3 N-glycome changes in type 1 diabetes complications |
title_full | Human complement component C3 N-glycome changes in type 1 diabetes complications |
title_fullStr | Human complement component C3 N-glycome changes in type 1 diabetes complications |
title_full_unstemmed | Human complement component C3 N-glycome changes in type 1 diabetes complications |
title_short | Human complement component C3 N-glycome changes in type 1 diabetes complications |
title_sort | human complement component c3 n-glycome changes in type 1 diabetes complications |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244649/ https://www.ncbi.nlm.nih.gov/pubmed/37293493 http://dx.doi.org/10.3389/fendo.2023.1101154 |
work_keys_str_mv | AT soicdinko humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT stambukjerko humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT tijardovicmarko humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT kesertoma humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT laucgordan humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT bulumtomislav humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT lovrencicmarijanavucic humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT rebrinasandravuckovic humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT tomicmartina humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT novokmetmislav humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT smircicduvnjaklea humancomplementcomponentc3nglycomechangesintype1diabetescomplications AT gornikolga humancomplementcomponentc3nglycomechangesintype1diabetescomplications |